FDA Lifts Partial Clinical Hold on Macrogenics' Linnet Study, Paving Way for Enrollment Resumption
MGNX has more than doubled off its 52-week low of $0.99.
Summary
The FDA has removed the partial clinical hold on MacroGenics' Linnet study for lorigerlimab, a key drug candidate for gynecologic cancers. This positive development follows the company's previous disclosure in its 10-K filing (March 9, 2026) that the study was under a partial hold. The removal allows MacroGenics to resume enrollment of new participants under a revised protocol with additional risk-mitigation measures. This is a material positive catalyst for the small-cap biotech, as it removes a significant regulatory overhang and enables the critical progression of a clinical asset. The company remains on track to provide a mid-year clinical update on the program.
At the time of this announcement, MGNX was trading at $3.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $219.3M. The 52-week trading range was $0.99 to $3.54. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.